Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
SUZHOU, China, March 26, 2026 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2025 and highlighted recent business progress. Key Highlights KN026 (Anbenitamab) achieved robust PFS and OS benefits in second- or third-line HER2-positive GC, with data presented as a LBA oral presentation at the 2025 ESMO [...]
2026-03-26 05:13:00